Regeneron, Sanofi get FDA nod for Dupixent to treat chronic rhinosinusitis with nasal polyps

This article was originally published here

The approval allows the drug firms to use Dupixent with other medicines for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not

The post Regeneron, Sanofi get FDA nod for Dupixent to treat chronic rhinosinusitis with nasal polyps appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply